Corxel SPAC deal with Amanat targets 377 million dollars for oral GLP 1 drug CX11

Corxel Pharmaceuticals plans to go public in the United States through a merger with a blank check company, in a Corxel SPAC deal meant to fund phase 3 trials of its oral GLP 1 drug CX11. The company and Amanat Acquisition Corp, listed on Nasdaq, announced a definitive business combination agreement on October 26. They expect about $377 million in gross proceeds before costs, assuming no Amanat shareholders redeem their shares. The deal is expected to close in the first half of 2027.

Terms of the Corxel SPAC agreement

The parties are Corxel Pharmaceuticals, Inc., the US arm of Corxel Pharmaceuticals Limited, and Amanat Acquisition Corp, a blank check company registered in the Cayman Islands. The joint release was filed with the Securities and Exchange Commission as an exhibit to Amanat's current report. According to the release, about $75 million sits in Amanat's trust account and about $300 million comes from a private investment in public equity, known as a PIPE. PIPE investors may cut their commitments one for one, with a matching cut in the price they pay, so the final amount can change. The combined company will list on the Nasdaq Capital Market under a new name and ticker, to be announced before closing.

The companies said the net proceeds should fund the business through 2029, including a global phase 3 programme for CX11 in obesity. The trust figure assumes no redemptions, and blank check shareholders can usually ask for their money back before a merger closes, so the cash delivered may be lower. The release does not give a pre money equity value. Corxel US will be led by its current management while it searches for a US based chief executive, with a new chief executive for the combined company expected at or before closing. Sandy Mou, chief executive of the Corxel group, and Pavan Cheruvu, chief executive of Amanat, are quoted in the release.

What the CX11 data show so far

CX11 is a once daily oral small molecule that acts on the GLP 1 receptor. In a US phase 2 obesity trial with a 36 week double blind treatment period, it produced mean body weight reduction of up to 11.5 percent under the efficacy estimand, the companies said. The efficacy estimand counts results as if people stayed on treatment, which tends to give larger numbers than an analysis that includes everyone who stopped. The release does not state the placebo result, the number of participants or the doses tested, and the data have not been published in a journal. Those gaps make it hard to compare CX11 with other oral candidates.

The release does not state the placebo result, the number of participants or the doses tested, and the data have not been published in a journal.

On tolerability, nausea was reported in 33 to 34 percent of participants across the CX11 dosing groups, vomiting in 12 to 16 percent, diarrhea in 4 to 12 percent and constipation in 2 to 12 percent. The companies said no severe nausea, vomiting, diarrhea or constipation was reported, and that stomach side effects were mostly mild to moderate and occurred mainly while doses were being raised. Overall, 5.0 percent of participants stopped because of stomach side effects. Kevin Xie, chief financial officer of Corxel US, said in the release that the company has aligned with the FDA on key elements of the regulatory path and phase 3 design after an end of phase 2 meeting.

Where CX11 comes from

Corxel did not discover CX11. In December 2024 it acquired worldwide rights outside Greater China to the drug, also known as VCT220, from the clinical stage biotech Vincentage, according to a December 2024 release. Financial terms were not disclosed. At that time, the drug had completed a phase 2 trial in China, and a registrational phase 3 study in people with obesity or overweight had begun there in November 2024. The new release describes CX11 as having completed phase 2 development in the United States and phase 3 development in Asia. Results from the Asian phase 3 work were not included, and the release does not say whether a filing is planned outside the United States.

The deal also carries a second, earlier asset. CX12 is an oral small molecule that acts on the amylin receptor and is in preclinical development, with several lead candidates under study. Corxel aims to file an investigational new drug application for CX12 in the first half of 2027. Amylin is a pancreatic hormone, and drugs that mimic it are being tested by several companies as a partner to GLP 1 agents for weight loss. A phase 1b study of higher CX11 doses is expected to report more data in the same half year. Those readouts will arrive before or around the expected closing date, which could affect how investors value the combined company.

What comes next for the Corxel SPAC

The Corxel SPAC transaction still has to close, and the cash it delivers will depend on redemptions and the PIPE terms. The joint release filed with the SEC carries the standard warnings that forward looking statements may not come true. CX11 would enter a field where oral GLP 1 options are arriving fast. The FDA approved Lilly's oral orforglipron for weight management in April 2026, and AstraZeneca has started phase 3 trials of its own small molecule, elecoglipron. The release gives no start date for the CX11 phase 3 programme or for its first results, and no approval timeline. Investors will be able to judge CX11 against those rivals only once full trial data appear.

For investors and clinicians, the key unknowns are the placebo adjusted weight loss, the size of the phase 2 trial and the long term safety record. None of those are in the release, and none should be inferred from the headline figure. The phase 1b readout at higher doses will be the next public data point on the drug. Readers should also note that a release issued alongside a financing has not been checked by independent reviewers. Our industry desk follows deals and financings in the peptide and incretin sector. The daily newswire carries each day's filings. How we handle company claims is set out in our editorial standards.

Conclusion

The Corxel SPAC deal with Amanat Acquisition Corp aims to raise about $377 million to take the oral GLP 1 drug CX11 into global phase 3 trials for obesity. The headline phase 2 result, up to 11.5 percent weight loss at 36 weeks, comes from a company release without placebo data or trial size. The money is not guaranteed until closing in 2027, and the drug's place in a crowded oral market remains unproven.